PARTNER 3

Ask MedXY AI

Latest news

Tag

CardiologyTAVRlong-term outcomes

Seven-Year Health Outcomes After TAVR Versus SAVR in Low-Risk Aortic Stenosis Patients: Insights from the PARTNER 3 Trial

By MedXY|Aug 18, 2026

In low-risk severe aortic stenosis patients, both TAVR and SAVR provide sustained health status improvements over seven years, with TAVR offering faster early recovery but similar long-term health outcomes.

Cardiologyaortic stenosisPARTNER 3

TAVR vs. Surgery in Low-Risk Patients: 7-Year PARTNER 3 Results Confirm Long-Term Parity

By MedXY|Feb 22, 2026

Seven-year data from the PARTNER 3 trial demonstrate that TAVR remains noninferior to surgical aortic-valve replacement in low-risk patients, with comparable rates of death, stroke, and valve durability, supporting TAVR as a sustained alter